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ABSTRACT: Examples of organometallic compounds as nucleoside analogues are rare within the field of medicinal bioor-
ganometallic chemistry. We report on the synthesis and properties of two chiral ferrocene derivatives containing both a nu-
cleobase and a hydroxyalkyl group. These so-called ferronucleosides show promising anticancer activity, with cytostatic 
studies on five different cancer cell lines indicating that both functional groups are required for optimal activity. 
Nucleoside analogues have long been established as an 
effective class of compound that exhibits antiviral or anti-
cancer activity.1 Two common structural features are a 
nucleobase moiety and a hydroxylmethyl group (Figure 1), 
which together allow them to act as substrates that adverse-
ly affect processes associated with nucleic acid synthesis. 
These two components are typically connected by an or-
ganic linker group that is a modification or a replacement 
of the sugar ring, which can either be cyclic (e.g. AZT) or 
acyclic (e.g. acyclovir).2 Due to their structural similarities 
to natural nucleosides, which can lead to resistance and 
side-effects, there is a continuing need for a diverse range 
of analogues with different structural features. Ferrocene 
has attracted active interest in recent years within the field 
of medicinal and bioorganometallic chemistry,3 with or-
ganometallic analogues and derivatives of the antimalarial 
drug chloroquine (ferroquine) and the breast cancer drug 
tamoxifen (the ferrocifen family) being the most widely 
known.4 At the same time there has been a number of ex-
amples of other ferrocene containing compounds that have 
shown anticancer,5 antibacterial and antifungal properties.6 
However although there are also some recent examples of 
ferrocene-conjugated nucleobases7 and hydroxylalkyl fer-
rocenes8  that exhibit anticancer activity, as far as we are 
aware, nucleoside analogues of the type shown in Figure 1 
that are bridged solely by an organometallic linker group 
and show biological activity have not been reported.9 
As part of our programme to develop novel metal-
containing analogues of DNA and its components,10 we 
recently reported an organometallic nucleic acid oligomer 
designated as Ferrocene Nucleic Acid (FcNA).10b The 
monomeric components of the reported form of FcNA 
consist of a tetra-substituted ferrocene unit containing two 
alkyl hydroxyl groups to allow connectivity via phos-
phodiesters, and two thymine nucleobases. We noticed that 
these monomeric compounds have the required features for 
a novel nucleoside analogue, where the 5-membered sugar 
ring is substituted for a 5-membered cyclopentadienyl ring 
of a ferrocene unit. Accordingly we now report bis-
substituted ferrocenes 1 and 2 (so-called ferronucleosides), 
that contain both a nucleobase (thymine or adenine) and a 
hydroxyl group, along with various control compounds 
(Fig. 2).  The cell line studies reported here demonstrate the 
promise of these ferrocenyl derivatives as a novel class of 
nucleoside analogue that show anticancer activity. 
Figure 1. Schematic representation of the structural relationship 
between thymidine and a nucleoside analogue that contains a 
variable linker group connecting a hydroxymethyl group with a 
nucleobase, with AZT (azidothymidine) as a specific example. 
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 Figure 2. Ferronucleosides 1 and 2 and controls 3-6. 
 
It was decided to first synthesize nucleoside analogues 
with a 1,2-disubstituted arrangement on one Cp ring, with 
the other Cp ring unfunctionalized. This would enable us to 
utilize the synthetic chemistry already developed within the 
group for FcNA monomer synthesis.10b For the same rea-
son, the compounds would have a three-carbon hydroxyl 
linker (with a methyl group on the alpha carbon to direct 
ortho-lithiation) and a two-carbon linker to the nucleobase. 
The synthetic route taken to make the ferronucleoside tar-
gets 1 and 2 is outlined in Scheme 1. The chirally pure Ugi 
amine11 7 was treated with n-BuLi and quenched with io-
dine to introduce the required planar 1,2-disubstitution 
pattern. Subsequent functional group inter-conversion gave 
compound 11, to provide the chain extension giving a three 
carbon linker. Treatment of 11 with silyl enol ether, 
catalysized by the Lewis acid boron trifluoride, gave com-
pound 12 in good yield. Reduction of the ester, followed by 
TBDPS protection gave compound 14. Conversion to alde-
hyde 15 (via n-BuLi halogen exchange and quenching with 
DMF) enabled a Wittig reaction to be performed to from 
alkene 16, with subsequent hydroboration-oxidation giving 
the mono-protected bis-alcohol 17 in high chiral purity (as 
checked by chiral HPLC analysis, overall 97% ee). The 
conversion of 17 to the target compounds 1 and 2 proceed-
ed via a Mitsunobu reaction with the appropriate protected 
nucleobase, followed by deprotection of the protecting 
groups. The family of compounds was also extended by 
making the control compounds 3-6 (Fig. 2), to assess the 
role of the alcohol and nucleobase groups, noting that com-
pound 6 had previously been shown8 to display antineo-
plastic activity against cervix carcinoma (HeLa) tumor 
cells. 
The cytostatic activity of six ferrocene compounds was 
evaluated in comparison to the established anticancer drugs 
cisplatin and 5-fluorouracil (5-FU) using a proliferation 
activity assay carried out on three tumor cell lines: murine 
leukemia cells (L1210), HeLa, and human T-lymphocyte 
cells (CEM). The data indicate that the concomitant pres-
ence of both the hydroxyl and nucleobase components are 
of crucial importance to give the highest cytostatic activity, 
with 1 and 2 exhibiting low to sub micromolar antiprolifer-
ative activity comparable with cisplatin (Table 1). In addi-
tion, 1 and 2 were almost equally as active as 5-FU in 
L1210 cell cultures, 2- to 5-fold less active in HeLa cell 
cultures, but 20-to 50-fold more active in CEM cell cul-
tures. Compounds 1 and 2 proved poorly toxic to non-
tumorigenic human embryonic lung (HEL) fibroblast cell 
cultures (minimal cytotoxic concentration: >50 µM).  
 
Scheme 1. Synthetic route towards ferrocene nucleoside 
analogues 1 and 2. 
 
Table 1. Cytostatic activity of compounds 1-4. 
Compound IC50 (µM)
a 
L1210 CEM HeLa 
1 0.78 0.9 2.68 
2 1.0 0.35 1.1 
3 12 39 45 
4 417 592 509 
5 26 49 94 
6 25 43 52 
Cisplatin 1 0.9 1.2 
5-FU 0.33 ± 0.17 18 ± 5 0.54 ± 0.12 
a50% inhibitory concentration, or compound concentration re-
quired to inhibit tumor cell proliferation by 50%. Data are the 
mean of at least two independent experiments. 
Cell growth studies carried out on an oesophageal cancer 
cell line revealed that compound 1 inhibited growth at 
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 concentrations of 6.25 µM, whereas control compounds 3 
and 4 (Figure 3 and supplementary data respectively) had 
much less or no effect, even up to higher concentrations of 
25 µM. The same trend was observed for the adenine com-
pound 2 and its control 5 (see supplementary data). Once 
again the data indicates that both functional groups (the 
hydroxyl in addition to the nucleobase) are required for the 
best cytostatic activities, which is comparable to cisplatin 
under these conditions. 
Assays of cellular viability (MTT assay) and cell prolif-
eration (BrdU assay) were then performed on colorectal 
cancer cell lines. The results after 48hr exposure (Figure 4) 
revealed that compounds 1 and 2 had anti-neoplastic activi-
ties approaching that 5-FU, whereas the other compounds 
were less effective. Encouragingly, an AMES assay to 
investigate the potential mutagenicity of these ferrocenyl 
derivatives revealed that the compounds were inactive.  
Figure 3. Growth curves for compound 1 (top) and 3 (bottom) at 
three different concentrations (LC = 6.25 µM, MC= 12.5 µM, HC 
= 25 µM) over 4 days in cancer cell line OE 19 (n = 3 ± SD). 
Figure 4. Cellular viability (MTT, blue) and cell proliferation 
(BrdU, red) assays on colorectal cell lines (48 hours). 
In conclusion, novel ferrocenyl nucleoside analogues 1 
and 2 appear to exhibit cytostatic activities that are compa-
rable under the conditions used to commercially established 
anticancer drugs such as cisplatin and 5-FU. Control stud-
ies indicate that the presence of both a hydroxyl and a nu-
cleobase group are required for optimal activity. This sug-
gests a mechanistic role for these novel bioorganometallic 
compounds involving an adverse affect on nucleic acid 
synthesis, as is the case for nucleobase analogue drugs 
containing organic linker groups.12 We are currently plan-
ning to carry out further studies to reveal the mode of ac-
tion of these ferronucleosides and to highlight stereochemi-
cal and structure activity relationships for improving bio-
logical activity and specificity.  
EXPERIMENTAL SECTION  
General Information: Unless stated otherwise, all re-
actions were performed under an Ar atmosphere. Com-
pound 6 was prepared as described previously.8 All tested 
compounds had a purity of ≥95%, as shown by HPLC (see 
supplementary information for data and conditions used).  
(R,Sp)-1-(α-N,N-Dimethylaminoethyl)-2-iodo-
ferrocene (8). The Ugi amine 711 (4.00 g, 15.56 mmol) was 
dissolved in Et2O (50 ml) at room temperature, n-BuLi (12 
ml, 30 mmol) was added and the mixture stirred overnight. 
The reaction mixture was cooled to -78°C and iodine (9.52 
g, 37.51 mmol), dissolved in THF (60 ml), was added over 
10 min. The reaction mixture was stirred at -78°C for 90 
min before being warmed to room temperature, at which 
point it was stirred for an additional 90 min before being 
quenched at 0°C with sodium thiosulfate(aq) (50 ml, 25% 
w/v). After dilution with Et2O (30 ml), the layers were 
separated and the aqueous layer further extracted with Et2O 
(3 x 50 ml). The combined organic fractions were dried 
over MgSO4, the solvent removed in vacuo before purifica-
tion via flash column chromatography (5% MeOH, 5% 
TEA in DCM) to yield product (3.18 g, 55%). 1H NMR 
(400 MHz, CDCl3) δ 4.46 (dd, J = 2.4, 1.4 Hz, 1H), 4.24 (t, 
J = 2.6 Hz, 1H), 4.15 (dd, J = 2.7, 1.3 Hz, 1H), 4.12 (s, 
5H), 3.62 (q, J = 6.8 Hz, 1H), 2.15 (s, 6H), 1.50 (d, J = 6.8 
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 90.21 (ipso Cp), 
74.32 (Fc), 71.67 (Fc), 68.19 (Fc), 65.59 (Fc), 57.59 (CH*), 
45.49 (ipso Cp), 41.22 (CH3), 16.01 (CH3). MS (ES) (m/z) 
calcd for C14H18N56FeI 382.9833, found 382.9820. IR (cm-
1): 3078 (=C-H), 2931 (CH2), 2878 (CH2), 2809 (CH2), 
1446 (CH3), 1371 (CH3), 1243, 1087, 821 (CH=CH), 732 
(CH Ar). Mp: 58°C-60°C.  
(R,Sp)-1-(α-Acetoxyethyl)-2-iodo-ferrocene (9). Com-
pound 8 (3.26 g, 8.51 mmol) and acetic anhydride (25.68 
ml, 272.17 mmol) were heated at 50°C for 2 hrs. The acetic 
anhydride was removed under high vacuum (0.1 mmHg) 
and the residue purified via flash column chromatography 
(10% EtOAc in hexane) to yield the yellow-brown oily 
product (2.94 g, 87%). 1H NMR (400 MHz, CDCl3) δ 5.89 
(q, J = 6.4 Hz, 1H), 4.51 (dd, J = 2.6, 1.4 Hz, 1H), 4.33 (dd, 
J = 2.8, 1.4 Hz, 1H), 4.28 (t, J = 2.6 Hz, 1H), 4.15 (s, 5H), 
2.01 (s, 3H), 1.66 (d, J = 6.5 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 170.30 (C=O), 87.54 (ipso Cp), 75.63 (Fc), 71.76 
(Fc), 69.71 (Fc), 68.94 (Fc), 65.80 (CH*), 44.03 (ipso Cp), 
21.16 (CH3), 18.66 (CH3). IR (cm-1): 3095 (=C-H), 2972 
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 (CH2), 2928 (CH2), 2866 (CH2), 1729 (C=O), 1445 (CH3), 
1371 (CH3), 1085, 820 (CH=CH), 703 (CH Ar).  
 (R,Sp)-1-(α-Hydroxyethyl)-2-iodo-ferrocene (10). 
Compound 9 (2.937 g, 7.37 mmol) was dissolved in EtOH 
(35 ml). NaOH(aq) (30 ml, 10% w/v) was added and the 
reaction was heated at 95°C for 15 min. After cooling to 
room temperature, the organic layer was extracted with 
EtOAc (2 x 40 ml). The organic layers were dried over 
Na2SO4, the solvent removed in vacuo and the residue 
purified via flash column chromatography (25% EtOAc in 
hexane) to yield the yellow oily product (2.43 g, 92%) 1H 
NMR (400 MHz, CDCl3) δ 4.85 (qd, J = 6.5, 2.8 Hz, 1H), 
4.46 (dd, J = 2.5, 1.4 Hz, 1H), 4.29 (dd, J = 2.7, 1.3 Hz, 
1H), 4.25 (t, J = 2.6 Hz, 1H), 4.14 (s, 5H), 1.88 (d, J = 3.6 
Hz, 1H), 1.62 (d, J = 6.5 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 91.61 (ipso Cp), 75.01 (Fc), 71.59 (Fc), 68.72 
(Fc), 66.51 (Fc), 64.98 (CH*), 43.62 (ipso Cp), 21.31 
(CH3). MS (ES) (m/z) calcd for C12H13O56FeI 355.9361, 
found 355.9352. IR (cm-1): 3255 (OH), 3093 (=C-H), 2967 
(CH2), 2920 (CH2), 1445 (CH3), 1369 (CH3), 1099 (C-OH), 
816 (CH=CH), 684 (CH=CH).  
(R,Sp)-1-(α-Methoxyethyl)-2-iodo-ferrocene (11). 
Compound 10 (2.43 g, 6.83 mmol) was dissolved in a 
MeOH/AcOH (20 ml, 9:1) mixture and the solution was 
stirred at room temperature for 48 hrs. The reaction was 
quenched with water (10 ml) and extracted with DCM 
(2×20 ml). The combined organic fractions were dried over 
MgSO4, the solvent removed in vacuo and the residue puri-
fied via flash column chromatography (25% EtOAc in 
hexane) to yield the yellow oily product (2.37 g, 94%). 1H 
NMR (400 MHz, CDCl3) δ 4.49 (dd, J = 2.4, 1.4 Hz, 1H), 
4.34 (q, J = 6.5 Hz, 1H), 4.29 – 4.25 (m, 2H), 4.13 (s, 5H), 
3.26 (s, 3H), 1.64 (d, J = 6.5 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 89.78 (ipso Cp), 74.78 (Fc), 74.22 (Fc), 71.66 
(Fc), 68.86 (Fc), 65.35 (CH*), 56.00 (CH3), 39.48 (ipso 
Cp), 19.63 (CH3). MS (ES) (m/z) calcd for C13H15O56FeI 
369.9517, found 369.9513. IR (cm-1): 3094 (=C-H), 2974 
(CH2), 2926 (CH2), 2871 (CH2), 2815 (CH2), 1448 (CH3), 
1371 (CH3), 1085 (C-O-C), 820 (CH=CH).  
 (S,Sp)-1-[α-Methyl(2-ethylpropanoate)]-2-iodo-
ferrocene (12). Compound 11 (2.37 g, 6.42 mmol) and 1-
ethoxyvinyloxytrimethylsilane (8.234 g, 51.37 mmol) were 
dissolved in DCM (30 ml). The mixture was cooled to -
78°C and BF3.OEt2 (1.77 ml, 14.12 mmol) was then added 
dropwise. The reaction mixture was stirred for 15 min at -
78°C before being warmed to room temperature and 
quenched with saturated NaHCO3 (40 ml). The organic 
layer was separated and the aqueous layer was further ex-
tracted with DCM (40 ml). The combined organic fractions 
were dried over MgSO4, the solvent removed in vacuo and 
the residue purified via flash column chromatography (10% 
EtOAc in hexane) to yield the yellow oily product (1.676 g, 
61%). 1H NMR (400 MHz, CDCl3) δ 4.42 (dd, J = 2.4, 1.4 
Hz, 1H), 4.18 – 4.08 (m, 7H+2H), 3.14 – 3.05 (m, 1H), 
2.53 (dd, J = 15.0, 3.7 Hz, 1H), 2.11 (dd, J = 15.0, 10.3 Hz, 
1H), 1.43 (d, J = 6.9 Hz, 3H), 1.25 (t, J = 7.2 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 172.00 (C=O), 94.07 (ipso Cp), 
74.12 (Fc), 71.52 (Fc), 67.84 (Fc), 64.58 (Fc), 60.26 (CH2), 
44.08 (ipso Cp), 43.19 (CH2), 30.72 (CH*), 18.90 (CH3), 
14.27 (CH3). MS (ES) (m/z) calcd for C16H19O256FeI 
425.9779, found 425.9782. 
(S,Sp)-1-[α-Methyl-(3-(hydroxyl)propyl)]-2-iodo-
ferrocene (13). Compound 12 (1.592 g, 3.73 mmol) was 
dissolved in Et2O (50 ml) and the solution was cooled to 
0°C. After standing for 5 min, diisobutylalumminum hy-
dride (11.2 ml, 11.2 mmol) was added slowly at that tem-
perature. The mixture was stirred at 0°C for 1 hr before the 
reaction was quenched with saturated sodium potassium 
tartrate in water (30 ml). The layers were separated and the 
aqueous layer was further extracted with Et2O (30 ml). The 
combined organic fractions were dried over Na2SO4, the 
solvent removed in vacuo and the residue purified via flash 
column chromatography (50% EtOAc in hexane) to yield 
the product (1.413 g, 99%). 1H NMR (400 MHz, CDCl3) δ 
4.42 (dd, J = 2.4, 1.4 Hz, 1H), 4.17 (td, J = 2.6, 0.6 Hz, 
1H), 4.13 (s, 5H), 4.06 (dd, J = 2.7, 1.3 Hz, 1H), 3.59 (t, J 
= 6.6 Hz, 2H), 2.78 – 2.69 (m, 1H), 1.72 – 1.52 (m, 2H), 
1.41 (d, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
95.87 (ipso Cp), 73.76 (Fc), 71.47 (Fc), 67.87 (Fc), 64.18 
(Fc), 60.84 (CH2), 44.73 (ipso Cp), 42.09 (CH2), 29.81 
(CH*), 19.69 (CH3). MS (ES) (m/z) calcd for C14H17O56FeI 
383.9674, found 383.9678. IR (cm-1): 3282 br (OH), 3088 
(=CH Fc), 2971 (CH2), 2932 (CH2), 2854 (CH2), 1556, 
1452 (CH2), 1376 (CH3), 680 (C=C). Mp: 96°C-98°C.  
(S,Sp)-1-[α-Methyl-(3-(tert-
butyldiphenylsilyloxy)propyl)]-2-iodo-ferrocene (14). 
Compound 13 (1.413 g, 3.67 mmol) was dissolved in DCM 
(20 mL) at room temperature. TEA (0.77 ml, 5.52 mmol), 
tert-butyldiphenylsilyl chloride (1.44 ml, 5.51 mmol) and 
DMAP (catalytic amount) were added to the mixture. The 
solution was then stirred overnight at room temperature 
before quenching with water (10 ml). The phases were 
separated and the aqueous layer was extracted with Et2O (2 
x 20 ml). The combined organic fractions were dried over 
Na2SO4, the solvent removed in vacuo and the residue 
purified via flash column chromatography (10% EtOAc in 
hexane) to yield a yellow oily product (2 g, 95%). 1H NMR 
(400 MHz, CDCl3) δ 7.70 – 7.65 (m, 4H), 7.43 – 7.32 (m, 
6H), 4.38 (dd, J = 2.4, 1.3 Hz, 1H), 4.10 (s, 5H+1H), 4.00 
(dd, J = 2.7, 1.3 Hz, 1H), 3.70 – 3.65 (m, 2H), 2.77 – 2.68 
(m, 1H), 1.88 – 1.80 (m, 1H), 1.43 – 1.34 (m, 1H), 1.31 (d, 
J = 6.9 Hz, 3H), 1.05 (s, 9H). 13C NMR (101 MHz, CDCl3) 
δ 135.63 (Ph), 134.10 (ipso Ph), 134.05 (ipso Ph), 129.47 
(Ph), 127.58 (Ph), 96.25 (ipso Cp), 73.81 (Fc), 71.38 (Fc), 
67.61 (Fc), 64.27(Fc), 62.10 (CH2), 44.45 (ipso Cp), 41.60 
(CH2), 30.03 (CH*), 26.94 (tBu), 19.24 (ipso tBu), 18.91 
(CH3). MS (ES) (m/z) calcd for C30H35O56FeISiNa 
622.0851, found 622.0846. IR (cm-1): 3071 (=CH Fc), 2958 
(CH2), 2929 (CH2), 2856 (CH2), 1472 (CH2), 1387 (CH3), 
1361, 1106, 1085, 821 (CH Ar TBDPS), 700 (C=C).  
(S,Sp)-1-[α-Methyl-(3-(tert-
butyldiphenylsilyloxy)propyl)]-2-formyl-ferrocene (15). 
Compound 14 (2.182 g, 3.51 mmol) was dissolved in Et2O 
(30 ml), the mixture was cooled to -78°C and n-BuLi (2.32 
ml, 7.01 mmol) was added. After 30 min, DMF (0.68 ml, 
8.76 mmol) was added and the mixture was stirred at -78°C 
for another 30 min before being allowed to warm to room 
temperature before quenching with water (20 ml). The 
phases were separated and the aqueous layer was extracted 
 with Et2O (2 x 20 ml). The combined ethereal fractions 
were dried over Na2SO4, the solvent removed in vacuo and 
the residue purified via flash column chromatography (10% 
EtOAc in hexane) to yield the red oily product (1.686 g, 
92%). 1H NMR (400 MHz, CDCl3) δ 10.11 (s, 1H), 7.68 – 
7.59 (m, 4H), 7.42 – 7.33 (m, 6H), 4.75 (dd, J = 2.7, 1.4 
Hz, 1H), 4.48 (t, J = 2.6 Hz, 1H), 4.43 (dd, J = 2.6, 1.4 Hz, 
1H), 4.21 (s, 5H), 3.61 (t, J = 7.1, 2H), 3.21 – 3.10 (m, 1H), 
1.73 – 1.50 (m, 2H), 1.34 (d, J = 6.9 Hz, 3H), 1.04 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 193.25 (C=O), 135.55 (Ph), 
133.94 (ipso Ph), 133.80 (ipso Ph), 129.55 (Ph), 127.61 
(Ph), 99.14 (ipso Cp), 76.31 (ipso Cp), 71.04 (Fc), 70.80 
(Fc), 70.03 (Fc), 68.89 (Fc), 61.75 (CH2), 43.28 (CH2), 
27.90 (CH*), 26.89 (tBu), 22.66 (ipso tBu), 19.17 (CH3). 
MS (ES) (m/z) calcd for C31H36O256FeSiNa 547.1732, 
found 547.1727. IR (cm-1): 3071 (=CH Fc), 2958 (CH2), 
2929 (CH2), 2856 (CH2), 1673 (C=O), 1589 (C=N), 1427 
(CH2), 1376 (tBu), 1106 (Si-OR), 1086 (Si-OR), 821 (CH 
Ar Ph), 700 (C=C). 
(S,Rp)-1-[α-Methyl-(3-(tert-
butyldiphenylsilyloxy)propyl)]-2-vinyl-ferrocene (16). 
Trimethylmethylphosphonium bromide (1.722 g, 4.82 
mmol), potassium tert-butoxide (0.541 g, 4.82 mmol) and a 
catalytic amount of dibenzo-18-crown-6-ether were dis-
solved in THF (20 ml). The mixture was stirred for 30 min 
and then 15 (1.686 g, 3.21 mmol), dissolved in THF (30 
ml), was added to the mixture. The reaction mixture was 
stirred overnight at room temperature, before quenching 
with water (10 ml) and extracting with Et2O (2 x 20 ml). 
The combined ethereal fractions were dried over Na2SO4, 
solvent removed in vacuo and purified via flash column 
chromatography (5% EtOAc in hexane) to yield the prod-
uct as a yellow oil (1.497 g, 89%). 1H NMR (400 MHz, 
CDCl3) δ 7.69 – 7.63 (m, 4H), 7.44 – 7.33 (m, 6H), 6.62 
(dd, J = 17.4, 10.8 Hz, 1H), 5.34 (dd, J = 17.5, 1.8 Hz, 1H), 
5.01 (dd, J = 10.8, 1.7 Hz, 1H), 4.43 (dd, J = 2.5, 1.4 Hz, 
1H), 4.12 (t, J = 2.6 Hz, 1H), 4.06 (dd, J = 2.5, 1.4 Hz, 1H), 
4.03 (s, 5H), 3.62 (dd, J = 7.2, 5.4 Hz, 2H), 2.94 – 2.86 (m, 
1H), 1.72 – 1.61 (m, 1H), 1.45 – 1.37 (m, 1H), 1.30 (d, J = 
6.8 Hz, 3H), 1.06 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 
135.59 (Ph), 134.08 (ipso Ph), 134.02 (ipso Ph), 133.50 
(CH vinyl), 129.49 (Ph), 127.56 (Ph), 110.96 (CH2 vinyl), 
94.84 (ipso Cp), 81.37 (ipso Cp), 69.66 (Fc), 66.55 (Fc), 
66.27 (Fc), 64.08 (Fc), 61.89 (CH2), 42.80 (CH2), 27.65 
(CH*), 26.89 (tBu), 19.23 (ipso tBu), 18.92 (CH3). MS 
(ES) (m/z) calcd for C32H38O56FeSi 522.2041, found 
522.2055. IR (cm-1): 3072 (=CH Fc), 2958 (CH2) 2930 
(CH2), 2857 (CH2), 1625 (Ar Ph), 1589, 1427 (CH2), 1388 
(CH3), 1105 (Si-OR), 1086 (Si-OR), 821 (CH Ar), 699 
(vinyl/C=C). 
(S,Rp)-1-[α-Methyl-(3-(tert-
butyldiphenylsilyloxy)propyl)]-[2-(hydroxyl)ethyl]-
ferrocene (17). Compound 16 (1.497 g, 2.87 mmol) was 
dissolved in THF (30 ml). BH3.THF (1M, 8.2 ml, 8.2 
mmol) was then added dropwise at room temperature and 
the mixture stirred for 2 hrs. EtOH (9.76 ml), NaOH (3M, 
9.76 ml, 29.28 moles) and H2O2 (30 wt. % in water, 7.17 
ml, 63.24 moles) were then successively added and the 
mixture stirred for 1 hr at room temperature. The reaction 
mixture was extracted with DCM (30 ml), washed with 
brine (20 ml) and then dried over Na2SO4. The solvent was 
removed in vacuo and the residue purified via flash column 
chromatography (10% EtOAc in hexane) to yield the yel-
low oily product (1.434 g, 82%). 1H NMR (400 MHz, 
CDCl3) δ 7.68 – 7.64 (m, 4H), 7.43 – 7.36 (m, 6H), 4.11 – 
4.09 (m, 1H), 4.05 (s, 5H), 4.00 (t, J = 2.5 Hz, 1H), 3.97 
(dd, J = 2.5, 1.3 Hz, 1H), 3.75 (tq, J = 6.8, 2.6 Hz, 2H), 
3.67 – 3.63 (m, 2H), 2.77 – 2.68 (m, 1H), 2.66 – 2.49 (m, 
2H), 1.74 – 1.66 (m, 1H), 1.43 – 1.32 (m, 1H), 1.26 (d, J = 
6.8 Hz, 3H), 1.06 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 
135.56 (Ph), 133.96 (ipso Ph), 129.59 (Ph), 127.63 (Ph), 
95.01 (ipso Cp), 82.31 (ipso Cp), 69.03 (Fc), 67.36 (Fc), 
65.39 (Fc), 65.15 (Fc), 63.00 (CH2), 61.98 (CH2), 42.43 
(CH2), 30.93 (CH2), 27.51 (CH*), 26.91 (tBu), 19.37 
(CH3), 19.22 (ipso tBu). MS (ES) (m/z) calcd for 
C32H40O256FeSiNa 563.2045, found 563.2039. IR (cm-1): 
3378 br (OH), 3072 (=CH Fc), 2930 (CH2), 2857 (CH2), 
1589, 1472 (CH3), 1427 (CH2), 1388 (tBu), 1361, 1105 (Si-
OR), 1086 (Si-OR), 819 (CH Ar Ph), 705 (C=C). HPLC: 
retention time 16.85 min; chiral AD column, 1% IPA in 
hexane, isocratic over 40 min (1 mL/min), ee 97%. 
(S,Rp)-1-[α-Methyl-(3-(hydroxy)propyl)]-2-
[(thyminyl)ethyl]-ferrocene (1). Triphenylphosphine (137 
mg, 0.516 mmol), 3-benzoyl thymine13 (95 mg, 0.447 
mmol) and compound 17 (0.186 g, 0.344 mmol) were dis-
solved in THF (10 ml) and stirred for 10 min at room tem-
perature. The flask was then covered with foil and DIAD 
(0.11 ml, 0.516 mmol) was added at room temperature 
before the mixture was heated at 65°C for 2 hrs. The reac-
tion mixture was evaporated, extracted with EtOAc (30 
ml), washed with brine (20 ml) followed by water (20 ml) 
and dried over Na2SO4. The solvent was removed in vacuo 
and the residue purified via flash column chromatography 
(30% EtOAc in hexane) to give the fully protected product 
(219 mg, 85%). Deprotection was achieved firstly by stir-
ring the compound in 5 ml of TBAF for 2 hr before the 
solvent was removed. The mixture was then redissolved in 
methylamine (33 wt. % in ethanol, 2 ml) and stirred at 
room temperature for an addition 30 min. The methylamine 
was evaporated and the crude was purified via flash column 
chromatography (5% MeOH in DCM) to give the product 
as a yellow oil (105 mg, 74%). 1H NMR (400 MHz, 
CDCl3) δ 9.44 (s, 1H), 7.07 (d, J = 1.2 Hz, 1H), 4.16 – 4.02 
(m, 8H), 3.99 – 3.88 (m, 1H), 3.74 – 3.55 (m, 3H), 2.96 – 
2.47 (m, 4H), 1.95 (d, J = 1.1 Hz, 3H), 1.75 – 1.64 (m, 1H), 
1.56 – 1.46 (m, 1H), 1.39 (d, J = 6.8 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 164.22 (C=O), 151.11 (C=O), 140.41 
(CH-thymine), 111.00 (ipso thymine), 95.36 (ipso Fc), 
80.77(ipso Fc), 69.30 (CH Cp), 67.63 (CH Cp), 65.97 (CH 
Cp), 65.37 (CH Cp), 60.27 (CH2), 49.84 (CH2), 43.24 
(CH2), 27.99 (CH2), 27.07 (CH), 19.25 (CH3 thymine), 
12.30 (CH3). MS (ES) (m/z) calcd for C21H26N2O3Na56Fe 
433.1191, found 433.1182. IR (cm-1): 3520-3291 br (OH), 
2957 (CH), 1677 (C=O). 
 (S,Rp)-1-[α-Methyl-(3-(hydroxy)propyl)]-2-[2-(-
adenin-9-yl)ethyl]-ferrocene (2). Triphenylphosphine 
(0.291 g, 1.109 mmol), N,N-6-dibenzoyl-adenine14 (0.381 
g, 1.109 mmol) and compound 17 (0.300 g, 0.555 mmol) 
were dissolved in THF (10 ml) and stirred for 10 min at 
room temperature. The flask was then covered with foil and 
 DIAD (0.24 ml, 1.109 mmol) was added at room tempera-
ture before the mixture was warmed up to 65°C for 2 hrs. 
The reaction mixture was evaporated, extracted with 
EtOAc (30 ml), washed with brine (20 ml) followed by 
water (20 ml) and dried over Na2SO4. The solvent was 
removed in vacuo and the residue purified via flash column 
chromatography (30% EtOAc in hexane) to give the pro-
tected product (0.343 g, 72%). Deprotection was achieved 
firstly by stirring the compound in TBAF (5 ml, 1M) for 2 
hr. The solvent was then removed and the residue redis-
solved in methylamine (33 wt. % in ethanol, 2 ml) and 
stirred at room temperature for an additional 30 min. The 
methylamine was then evaporated and the crude mixture 
purified via flash column chromatography to give the prod-
uct as a yellow solid (170 mg, 73%). 1H NMR (400 MHz, 
DMSO-d6) δ 8.19 (s, 1H), 8.17 (s, 1H), 7.21 (s, 2H), 4.41 – 
4.33 (m, 2H+1H (OH)), 4.11 (s, 5H), 4.02 (d, J = 2.4 Hz, 
2H), 3.99 (t, J = 2.4 Hz, 1H), 3.42 – 3.28 (m, 2H), 2.97 – 
2.75 (m, 2H), 2.75 – 2.67 (m, 1H), 1.53 – 1.45 (m, 1H), 
1.32 (d, J = 6.8 Hz, 3H+1H). 13C NMR (101 MHz, DMSO-
d6) δ 155.95 (ipso adenine), 152.43 (CH adenine), 149.39 
(ipso adenine), 140.71 (CH adenine), 118.75 (ipso ade-
nine), 94.43 (ipso Cp), 81.89 (ipso Cp), 68.80 (Cp), 66.46 
(Cp), 64.92 (Cp), 64.74 (Cp), 58.66 (CH2), 43.10 (CH2), 
42.43 (CH2), 27.98 (CH2), 27.10 (CH*), 19.38 (CH3). MS 
(ES) (m/z) calcd for C21H26N5O56Fe 420.1487, found 
420.1484. IR (cm-1): 3348 br (OH), 3270 (NH2), 3240 
(NH2), 3098 (=CH Fc), 2955 (CH2), 2926 (CH2), 2871 
(CH2), 1674 (C=N), 1604 (NH2), 1574 (NH2), 1305 (OH), 
1076 (C-O), 814 (CH Ar). Mp: 90°C-92°C.  
1-[α-Methyl-(3-(hydroxy)propyl)]ferrocene (3). (S)-
3-Ethoxy-1-methyl-3-oxopropylferrocene15 (220 mg, 0.733 
mmol) was dissolved in diethyl ether (10 ml). LiAlH4 (56 
mg, 1.466 mmol) was added carefully and the resulting 
suspension was left to stir for 1 hr. The reaction was 
quenched with saturated sodium potassium tartrate (10 ml), 
extracted with diethyl ether (2 x 20ml), dried over MgSO4 
and the solvent removed in vacuo. The residue was purified 
via flash column chromatography to give the product as a 
yellow oil (100 mg, 58%). 1H NMR (300 MHz, CDCl3) δ 
4.13 (s, 5H), 4.09 – 4.04 (m, 4H), 3.67 (q, J = 6.2 Hz, 2H), 
2.74 – 2.53 (m, 1H), 1.85 – 1.61 (m, 2H), 1.27 (d, J = 6.9 
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 95.41 (ipso Cp), 
68.51 (CH Cp), 67.22 (CH Cp), 67.12 (CH Cp), 67.07 (CH 
Cp), 65.70 (CH Cp), 61.12 (CH2), 41.47 (CH2), 29.62 
(CH), 20.64 (CH3). MS (ES) (m/z) calcd for C14H18O256Fe 
258.0707, found 258.0708. IR (cm-1): 3512-3146 br (OH), 
2933 (CH), 1052 (C-O). 
1-(Thyminyl-)ethyl-ferrocene (4). Triphenylphosphine 
(348 mg, 1.30 mmol), N-3-benzoylthymine13 (223 mg, 1.04 
mmol), and 2-ferrocenylethanol16 (200 mg, 0.87 mmol) 
were dissolved in THF (10 ml) and stirred for 10 min at 
room temperature. The flask was then covered with foil and 
DIAD (0.28 ml, 1.30 mmol) was added at room tempera-
ture before the mixture was heated at 65°C for 2 hrs. The 
solvent was then evaporated and the residue extracted with 
EtOAc (30 ml), washed with brine (20 ml) and water (20 
ml) and dried over Na2SO4, before the solvent was removed 
in vacuo. Deprotection was achieved by treating the crude 
mixture with methylamine solution (33 wt. % in ethanol, 5 
ml) for 30 min. The solvent was then evaporated in vacuo 
and the residue purified via flash column chromatography 
(40% EtOAc in hexane) to give the product (176 mg, 60%). 
1H NMR (300 MHz, CDCl3) δ 8.29 (s, 1H), 6.70 (d, J = 1.2 
Hz, 1H), 4.15 (s, 5H), 4.13 – 4.09 (m, 2H), 4.04 (t, J = 1.8 
Hz, 2H), 3.79 (t, J = 7.1 Hz, 2H), 2.73 (t, J = 7.1 Hz, 2H), 
1.85 (d, J = 1.2 Hz, 3H). 13C NMR (101 MHz, CDCl3 trace 
of MeOD) δ 216.94 (ipso thymine), 193.73 (C=O), 181.71 
(C=O), 141.17 (CH-thymine), 83.57 (ipso-Cp), 68.63(CH-
Cp), 68.37(CH-Cp), 67.94 (CH-Cp), 50.20 (CH2), 29.17 
(CH2), 11.98 (CH3). MS (ES) (m/z) calcd for 
C17H18N2O256Fe 338.0718, found 338.0720. Mp: degraded 
at 235°C. IR (cm-1): 3146 (NH), 2999 (CH), 1683 (C=O), 
1644 (NH bending). 
1-[2-(Adenin-9-yl)ethyl]-ferrocene (5). Tri-
phenylphosphine (0.383 g, 1.46 mmol), N,N-6,6-dibenzoyl-
adenine14 (0.500 g, 1.46 mmol) and 2-ferrocenylethanol16 
(0.201 g, 0.73 mmol) were dissolved in THF (10 ml) and 
stirred for 10 min at room temperature. The flask was then 
covered with foil and DIAD (0.24 ml, 1.18 mmol) was 
added at room temperature before the mixture was warmed 
up to 65°C for 2 hrs. The reaction mixture was evaporated, 
extracted with EtOAc (30 ml), washed with brine (20 ml) 
followed by water (20 ml) and then dried over Na2SO4. The 
solvent was removed in vacuo and purified via flash col-
umn chromatography (40% EtOAc in hexane) to give the 
bis-protected product (0.134 g, 33%). Deprotection was 
achieved by dissolving the compound (0.055 g, 0.1 mmol) 
in methylamine (33 wt. % in ethanol, 3 ml) and stirring at 
room temperature for 30 min. The methylamine was then 
evaporated and the residue purified via flash column chro-
matography (95/5 DCM/MeOH) to give the product as a 
yellow solid (0.019 g, 58%). 1H NMR (400 MHz, DMSO-
d6) δ 8.17 (s, 1H), 8.05 (s, 1H), 7.17 (s, 2H), 4.31 (dd, J = 
8.2, 6.8 Hz, 2H), 4.15 (s, 5H), 4.08 – 4.02 (m, 4H), 2.85 (t, 
J = 7.5 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ 155.89 
(ipso adenine), 152.35 (CH adenine), 149.40 (ipso ade-
nine), 140.76 (CH adenine), 118.73 (ipso adenine), 84.39 
(ipso Cp), 69.00 (Fc), 68.55 (Fc), 43.75 (CH2), 29.34 
(CH2). MS (ES) (m/z) calcd for C17H18N556Fe 348.0912, 
found 348.0920 (M+ + H+). IR (cm-1): 3399 (NH2), 3316 
(NH2), 3084 (=CH Fc), 2980 (CH2), 2931 (CH2), 2907 
(CH2), 1653 (C=C), 1596 (NH2), 1435 (CH2), 1245, 797 
(CH Ar). Mp: 142°C (decomp). 
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